Portal de Periódicos da CAPES

Ticlopidine‐associated cholestatic hepatitis

2002; Wiley; Volume: 32; Issue: 7 Linguagem: Inglês

10.1046/j.1445-5994.2002.00241.x

1445-5994

Lisa C. Adams, G. Jeffrey, Bastiaan DeBoer, George Garas,

Drug Transport and Resistance Mechanisms

Internal Medicine JournalVolume 32, Issue 7 p. 359-360 Ticlopidine-associated cholestatic hepatitis L. Adams, L. Adams Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital,Search for more papers by this authorG. P. Jeffrey, G. P. Jeffrey Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital, Department of Medicine, The University of Western Australia andSearch for more papers by this authorB. Deboer, B. Deboer PathCentre, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, AustraliaSearch for more papers by this authorG. Garas, G. Garas Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital,Search for more papers by this author L. Adams, L. Adams Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital,Search for more papers by this authorG. P. Jeffrey, G. P. Jeffrey Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital, Department of Medicine, The University of Western Australia andSearch for more papers by this authorB. Deboer, B. Deboer PathCentre, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, AustraliaSearch for more papers by this authorG. Garas, G. Garas Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital,Search for more papers by this author First published: 26 June 2002 https://doi.org/10.1046/j.1445-5994.2002.00241.xCitations: 11 Leon Adams, Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital, Monash Ave., Nedlands, WA 6009, Australia. Email: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Hass WK, Easton JD, Adams HP et al. A randomised trial comparing ticlopidine hydrochloride with aspirinfor the prevention of stroke in high risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501−7. 2 Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic drug regimens aftercoronary artery stenting. N Engl J Med 1998; 339: 1665−71. 3 Balsano F, Rizzon P, Violi F et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenterclinical trial. The Studio della Ticlopidina nell'Angina Instablile Group. Circulation 1990; 82: 17−26. 4 Sossai P, Corte GD, Marenzi R. Liver injury with the use of ticlopidine. Ann Pharmacol 1998; 32: 1370−1. 5 Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215−20. 6 Amaro P, Nunes A, Macoas F et al. Ticlopidine induced prolonged cholestasis: a case report. EurJ Gastroenterol Hepatol 1999; 11: 673−6. Citing Literature Volume32, Issue7July 2002Pages 359-360 ReferencesRelatedInformation